Search

Displaying results 8451 - 8460 of 9881 in total
  1. Drug

    Phenylbutyric acid

    go.drugbank.com/drugs/DB06819
    ApprovedInvestigational

    Phenylbutyric acid is a fatty acid and a derivative of [butyric acid] naturally produced by colonic bacteria fermentation. … It demonstrates a number of cellular and biological effects, such as relieving inflammation and acting as a chemical chaperone.

  2. Drug

    Antazoline

    go.drugbank.com/drugs/DB08799
    Approved

    Antazoline is a 1st generation antihistamine with anticholinergic activity. It is used to relieve nasal congestion.

    Mixtures: Albalon A, Zincfrin AInternational brands: Vasocon-a
  3. Drug

    Isothipendyl

    go.drugbank.com/drugs/DB08802
    Investigational

    Isothipendyl is an antihistamine and anticholinergic used as an antipruritic.

  4. Drug

    Bupranolol

    go.drugbank.com/drugs/DB08808
    Experimental

    Bupranolol is a non-selective beta blocker with potency similar to [propanolol]. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.

  5. Drug

    Gabapentin enacarbil

    go.drugbank.com/drugs/DB08872
    Approved

    It is a prodrug of gabapentin, and indicated in adults for the treatment of Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).

  6. Drug

    Perampanel

    go.drugbank.com/drugs/DB08883
    ApprovedInvestigational

    Perampanel is a noncompetitive AMPA glutamate receptor antagonist.

  7. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 201...

    Categories: UGT1A9 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  8. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    [L45583] Trametinib is currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer, as monotherapy or in combination with [dabrafenib], a

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  9. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index
  10. Drug

    Afatinib

    go.drugbank.com/drugs/DB08916
    ApprovedInvestigational

    Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. … For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected